Key result
Simvastatin added to conventional therapy significantly reduced right ventricular mass by 29.1 g compared to placebo over 6 months in patients with pulmonary arterial hypertension.
Why the study?
Does simvastatin reduce right ventricular mass in patients with pulmonary arterial hypertension?
RCT (n=42)
Double-blind
Randomized
Yes
Does simvastatin reduce right ventricular mass in patients with pulmonary arterial hypertension?
Mean Difference: -29.1
Absolute Event Rate: -25.2% vs 3.9%
p-value: p=0.028
Simvastatin added to conventional therapy in patients with pulmonary arterial hypertension produces a small, transient reduction in RV mass and NT-proBNP at 6 months that is not sustained at 12 months.
Transient RV mass reduction at 6 months lacks sustained benefit in PAH; challenges long-term simvastatin efficacy.
No takes yet. Share an insight, caveat, or question.
Wilkins et al. (2010) conducted an RCT in Pulmonary arterial hypertension (n=42). Simvastatin vs. Placebo was evaluated on Change in right ventricular (RV) mass from baseline to 6 months (MD -29.1, p=0.028). Simvastatin added to conventional therapy significantly reduced right ventricular mass by 29.1 g compared to placebo over 6 months in patients with pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: